3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
23
Neoplasm Metastasis
3
Metastatic Castration-Resistant Prostate Cancer
3
Recurrence
2
Neoplasms
2
Bulbo-Spinal Atrophy, X-Linked
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer Metastatic
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Lymphoma, Follicular
1
Castrate Sensitive Prostate Cancer
1
Breast Neoplasms
1
Bites and Stings
1
Adenocarcinoma
1
Interventions
durvalumab
2
Tretinoin
2
Paclitaxel
2
Carboplatin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
STA 9090
1
SGN-LIV1A
1
Pemetrexed
1
MK 2206
1
Letrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
enzalutamide
×
30 days
×
Clear all
No trials found.